What we’re doing to make sure people with Parkinson’s in Scotland get their time critical medication on time Date 2 May 2025
Research shows bad dreams could predict future memory and thinking problems Date 14 August 2020 Researchers in Portugal have discovered that the content of dreams, particularly those with negative emotions, may predict long-term cognitive decline in people with Parkinson’s.
Link found between diabetes and increased Parkinson’s risk Date 11 August 2020 An international team of researchers have uncovered a biological link that may account for why those with diabetes have a higher risk of developing Parkinson’s.
Parkinson’s UK commit further funding to develop drugs that protect mitochondria Date 4 August 2020 We’re investing a further £1 million to drive forward drugs that target energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
Parkinson’s UK continues drug discovery with NRG Therapeutics Ltd. Date 3 August 2020 Parkinson's UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme.
How have coronavirus (COVID-19) restrictions impacted people affected by Parkinson’s? Date 2 July 2020 With Lancaster University, we conducted a survey that shows the coronavirus restrictions are having a big impact on the lives and the health of people affected by Parkinson’s.
Our response to Black Lives Matter Date 15 June 2020 Parkinson’s UK chose to stay quiet during the recent Black Lives Matter conversations. We believed that by giving others space to have their voices heard, we were playing a role in supporting their message. We were wrong.
Researchers identify key player in genetic Parkinson’s Date 29 April 2020 A team of researchers at the University of York have shown a protein called Rab10 plays an important role in the loss of brain cells in LRRK2-associated Parkinson’s.
Cannabis extract may hold key to stop pain in Parkinson's Date 5 March 2020 Cannabis-based compounds could be the silver bullet to relieve pain for people with Parkinson’s according to the largest ever study into pain and the condition.
Potential treatment for dyskinesia in Parkinson’s Date 2 March 2020 Results from a one-year project, funded through the Parkinson’s Virtual Biotech, suggest that NLX-112 has potential as a future treatment for reducing dyskinesia and improving movement symptoms of Parkinson’s.
Initial results from CDNF clinical trial announced Date 26 February 2020 Herantis Pharma has published initial results from a phase 1/2 study of an experimental protective protein called CDNF which may hold potential to slow, stop or reverse Parkinson's.
